Estimated Read Time:

1 minute

SABCS Snippets: SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer

Junjie Li, MD, associate chief physician at Fudan University Shanghai Cancer Center, Shanghai, China, talks with Saba Shaikh, MD, about the HER2-directed antibody-drug conjugate SHR-A1811 in the neoadjuvant treatment of HER2-positive early breast cancer.

Share


Recent Posts

Upcoming Key Dates

October 30 – Abstract Titles Released*

November 3 – Advance Registration Rates End

November 6 – Child Care Advance Registration Deadline

November 17 – Housing Reservations Close

November 24 – Full Abstract Text Released*

December 1 – SABCS App Available*

December 9 – SABCS 2025 Begins

*approximate dates